4D Molecular Therapeutics FDMT EBITDA

EBITDA at other companies

Eli LillyLLY

$9.78B+34.8%

Regeneron PharmaceuticalsREGN

$1.42B+16.7%

Vertex PharmaceuticalsVRTX

$1.19B+76.0%

EyePoint, Inc.EYPT

-$96.69M-56.7%

AbbVieABBV

$5.93B+2.7%

RegenxbioRGNX

$33.02M+156%

FAQ

What is 4D Molecular Therapeutics's EBITDA?

4D Molecular Therapeutics (FDMT) reported EBITDA of -$72.35M in Q1 2026.

How has 4D Molecular Therapeutics's EBITDA changed year-over-year?

4D Molecular Therapeutics's EBITDA decreased by 37.6% year-over-year, from -$52.57M to -$72.35M.

What is the long-term trend for 4D Molecular Therapeutics's EBITDA?

Over 4 years (2021 to 2025), 4D Molecular Therapeutics's EBITDA has grown at a 24.8% compound annual growth rate (CAGR), from -$69.81M to -$169.57M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.